Paclitaxel (HY-B0015) for cancer research. Navicixizumab can be used in the research of ovarian, primary peritoneal, or fallopian tube cancer." inertia="description"> Paclitaxel (HY-B0015) for cancer research. Navicixizumab can be used in the resea, Navicixizumab, , , " inertia="keywords">
Cart summary

You have no items in your shopping cart.

Navicixizumab

Navicixizumab

Catalog Number: orb2703343

DispatchUsually dispatched within 5-10 working days
$ 3,370.00
Catalog Numberorb2703343
CategoryAntibodies
DescriptionNavicixizumab (OMP-305B83) is a bispecific anti-VEGF and anti-DLL4 inhibitory antibody. Navicixizumab can combine with Paclitaxel.html" class="link-product" target="_blank"> Paclitaxel (HY-B0015) for cancer research. Navicixizumab can be used in the research of ovarian, primary peritoneal, or fallopian tube cancer.
CAS Number[1638338-43-8]
ConjugationUnconjugated
TargetNavicixizumab
StorageMaintain refrigerated at 2-8°C for up to 2 weeks. For long term storage store at -20°C in small aliquots to prevent freeze-thaw cycles.
NoteFor research use only
Expiration Date12 months from date of receipt.
  • Anti-DLL4 Reference Antibody (navicixizumab) [orb1806225]

    ELISA,  FA,  FACS,  Kinetics

    Human

    Monoclonal

    Unconjugated

    50 μg, 100 μg, 1 mg, 5 mg
  • Anti-DLL4 Reference Antibody (navicixizumab) [orb1818447]

    ELISA,  FC

    Human, Monkey

    Monoclonal

    Unconjugated

    100 μg
  • Navicixizumab (DLL4/VEGFA) - Research Grade Biosimilar [orb1237511]

    Recombinant

    Unconjugated

    0.1 mg
  • Navicixizumab [orb1140914]

    Unconjugated

    5 mg, 1 mg
  • Navicixizumab [orb1980573]

    Unconjugated

    5 mg